A Phase 2, Open-Label, Sequential Group, Investigator Blinded Study of Magnetic Resonance Spectroscopy (31P-MRS) to Assess the Effects of CNM-Au8 for the Bioenergetic Improvement of Impaired Neuronal Redox State in Multiple Sclerosis
Latest Information Update: 03 Feb 2025
At a glance
- Drugs CNM Au8 (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- Acronyms REPAIR-MS
- Sponsors Clene Nanomedicine
Most Recent Events
- 29 Jan 2025 Planned End Date changed from 1 Dec 2024 to 1 Jun 2025.
- 29 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Apr 2025.
- 29 Jan 2025 Status changed from active, no longer recruiting to completed.